Abstract
To date, efforts of developing successful vaccine that targets specific epitopes of anthrax lethal toxin components, viz., protective antigen (PA) and lethal factor (LF), have been limited as evident by a handful of research publication on efficacious peptide vaccines against anthrax. Present study aims in this direction, and as a preliminary step in the development of vaccine, humoral response of peptide cocktails consisting of antigenic epitope sequences of anthrax lethal toxin components has been evaluated. Four peptide cocktail combinations were made from five PA peptides and two LF peptide sequences which were known to be antigenic and software predicted B-cell epitopes. Enzyme-linked immunosorbent assay result from all four peptide cocktail combinations revealed that two combinations PC 4 + 1 and PC 4 + 4 showed good anti-PA and anti-LF IgG antibody response with predominant IgG1 and IgG2b antibodies. Both anti-PA and anti-LF avidity of peptide cocktails were determined and were found to be higher than their respective native proteins. Overall, the results obtained from this study give a promising hope of developing a successful peptide vaccine candidate against anthrax.
This is a preview of subscription content, log in via an institution to check access.
References
Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D (2002) Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun 70:6231–6241
Backert L, Kohlbacher O (2015) Immunoformatics and epitope prediction in the age of genomic medicine. Genome Med 7:119
Bellanti JA, Lin FYC, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R (2012) Phase I study of recombinant mutant protective antigen of Bacillus anthracis. Clin Vaccine Immunol 19:140–145
Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culberstone N, Bartholomew RM, Theofan G, Milano J, Offner H, Vandenbark AA (2005) A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler 11:552–561
Chitlaru T, Altboum Z, Reuveny S, Shafferman A (2010) Progress and novel strategies in vaccine development and treatment of anthrax. Immunol Rev 239:221–236
Engvall E, Perlman P (1971) Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 8:871–874
Hu M, Li J, Yao SQ (2008) In-situ click assembly of small molecule matrix metalloprotease inhibitor containing zinc chelating groups. Org Lett 10:5529–5531
Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477–484
Lopez JA, Weilenman C, Audran R, Roggero MA, Bonelo A, Tiercy JM, Spertini F, Corradin G (2001) A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccine strategies. Eur J Immunol 31:1989–1998
Malkevich NV, Basu S, Rudge TL, Clement KH, Chakrabarti AC, Aimes RT, Nabros GS, Skiadopoulos MH, Ionin B (2013) Effect of anthrax immune globulin on response to biothrax (Anthrax vaccine adsorbed) in New Zealand white rabbits. Antimicrob Agents Chemother 57:5693–5696
Pullen GR, Fitzgerald MG, Hosking CS (1986) Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 86:83–87
Purcell AW, McClusley J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404–414
Slingluff CL Jr (2011) The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 17:343–350
Sundaram R, Lynch MP, Rawale SV, Sun Y, Kazanji M, Kaumaya PT (2004) De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem 279:24141–24151
Suryanarayana N, Vanlalhmuaka, Thavachelvam K, Tuteja U (2015) In-silico design and antibody response to the peptide sequences from protective antigen and lethal factor toxins of Bacillus anthracis. Ind J Curr Microbiol Adv Sci 4:859–867
Tambunan USM, Sipahutar FRP, Parikesit AA, Kerami D (2016) Vaccine design for H5N1 based on B- and T-cell epitope prediction. Bioinform Biol Insights 10:27–35
Verma SK, Yadav S, Kumar A (2015) In-silico prediction of B- and T- cell epitope on Lassa virus proteins for peptide based subunit vaccine design. Adv Biomed Res 4:201
Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, Gamble CS, Twenhafel NA, Ivins BE, Heine HS, Sheeler R, Wright ME, Friedlander AM (2006) Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci 103:7813–7816
Weiss MM, Weiss PD, Weiss JB (2007) Anthrax vaccine and public health policy. Am J Public Health 97:1945–1951
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Suryanarayana, N., Vanlalhmuaka, Thavachelvam, K., Tuteja, U. (2017). Humoral Responses of In Silico Designed Immunodominant Antigenic Peptide Cocktails from Anthrax Lethal Toxin Components. In: Shukla, P. (eds) Recent advances in Applied Microbiology . Springer, Singapore. https://doi.org/10.1007/978-981-10-5275-0_12
Download citation
DOI: https://doi.org/10.1007/978-981-10-5275-0_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-5274-3
Online ISBN: 978-981-10-5275-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)